Chimeric antigen receptor T-cell therapy, or CAR T, has dramatically improved the treatment of certain blood cancers. Initially approved for patients who had failed multiple lines of therapy, clinical trials have shown CAR ...
Jan 17, 2024
0
36
Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, is cost-effective for second-line diffuse large B-cell lymphoma (DLBCL) therapy, according to a study published online Dec. 28 in Blood ...
Jan 4, 2024
0
0
Cedars-Sinai Cancer investigators have discovered a new way to predict whether a cancer of the immune system will recur in patients treated with a bone marrow transplant. Their study, published in the Journal of Clinical ...
Dec 21, 2023
0
0
A new review paper titled "Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in Brazil: Balancing efficacy, safety, and tolerability" has been published in Oncotarget.
Dec 20, 2023
0
0
Treatment with bendamustine prior to CAR T-cell therapy in patients with refractory large B-cell lymphoma associates with poorer treatment outcomes, finds a recent study.
Dec 19, 2023
0
1
A study by researchers at Columbia and the Hong Kong University of Science and Technology is helping to clarify how low-grade lymphoma changes as it develops into a more aggressive tumor, which could lead to the development ...
Dec 18, 2023
0
29
Proteasomes are protein-degrading complexes that are important for cancer cell survival. Proteasome inhibitors are commonly used to treat diseases such as multiple myeloma and mantle cell lymphoma. Proteasomes have three ...
Dec 14, 2023
0
15
Researchers have come one step closer to answering why, in some patients, a type of lymphoma changes from indolent to aggressive, and in particular, they are closer to identifying which patients are at high risk of this change ...
Dec 12, 2023
0
4
A Stanford Medicine-led, international study of hundreds of samples from patients with Hodgkin lymphoma has shown that levels of tumor DNA circulating in their blood can identify who is responding well to treatment and others ...
Dec 11, 2023
0
38
Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine say a new combination of antibody therapies produced a "surprisingly high" response ...
Dec 11, 2023
0
0
